Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	КҮ	MD	NJ	NV	NY	TN	TX	WA
Applicable	Х	Х	NA	NA	Х	NA	Х	Х	Х	Х	Х	NA	NA	Х

^{*}FHK- Florida Healthy Kids

Osmolex ER (amantadine extended-release tablets)

Override(s)	Approval Duration						
Prior Authorization	1 year						
Quantity Limit							

Medications	Quantity Limit
Osmolex ER	May be subject to quantity limit
(amantadine extended-release tablets)	

APPROVAL CRITERIA

Requests for Osmolex ER (amantadine extended-release) may be approved if the following criteria are met:

- I. Individual is using for one of the following:
 - A. Parkinson's disease: **OR**
 - B. Drug-induced extrapyramidal reactions in adults.

Osmolex ER (amantadine extended-release) may not be approved for:

Individuals with end-stage renal disease (creatinine clearance below 15 mL/min/1.73 m²).

Note: Osmolex ER is not interchangeable with other amantadine immediate-or extended-release products.

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	КҮ	MD	NJ	NV	NY	TN	TX	WA
Applicable	Х	Х	NA	NA	Х	NA	Х	Х	Х	Х	Χ	NA	NA	Х

^{*}FHK- Florida Healthy Kids

State Specific Mandates								
State name N/A	Date effective N/A	Mandate details (including specific bill if applicable) N/A						

Key References:

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018. URL: http://www.clinicalpharmacology.com. Updated periodically.

DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. http://dailymed.nlm.nih.gov/dailymed/about.cfm. Accessed January 3, 2018.

DrugPoints® System (electronic version). Truven Health Analytics, Greenwood Village, CO. Updated periodically.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.